Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity
NCT02919683Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Nov 2016
- Primary completion
- Jul 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in squamous cell carcinoma of the oral cavity (OSCC), sponsored by Dana-Farber Cancer Institute. Started Nov 2016; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
squamous cell carcinoma of the oral cavity (OSCC)
Beyond the preview
Go deeper on NCT02919683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02919683.